Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | PLAT | P00750 | 1/20 | 0.42 |
| ▸ | PPIB | P23284 | 1/20 | 0.42 |
| ▸ | PPIA | P62937 | 1/20 | 0.42 |
| ▸ | PPID | Q08752 | 1/20 | 0.42 |
| ▸ | PPIG | Q13427 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.40 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.40 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4019989 | 0.87 | TPSAB1 (0.54) | MEN1KMT2ASMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL27571682 | 0.86 | TSHR (0.51) | MEN1KMT2ASMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL20467743 | 0.86 | MEN1 (0.44) | MEN1KMT2ASMN1; SMN2L3MBTL1F2 | |
| SCHEMBL28861927 | 0.85 | NPC1 (0.51) | MEN1KMT2ASMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL27811154 | 0.85 | SMN1; SMN2 (0.44) | MEN1KMT2ASMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL27574189 | 0.84 | NPC1 (0.48) | SMN1; SMN2L3MBTL1PPIBPPIAPPID | |
| SCHEMBL28861926 | 0.83 | MAPT (0.56) | MEN1KMT2ASMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL27805750 | 0.83 | MEN1 (0.43) | MEN1KMT2ASMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL27848344 | 0.83 | MEN1 (0.43) | MEN1KMT2ASMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL27532962 | 0.83 | LMNA (0.51) | MEN1KMT2ASMN1; SMN2L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106573899-B | Optionally fused, heterocyclyl-substituted pyrimidine derivatives for the treatment of inflammatory, metabolic, neoplastic and autoimmune diseases | 纽韦卢森公司 | 2021-04-06 | — | — | CN | disclosed |
| CN-109970675-A | One group of thiourea compound and its preparation method and application | 中国医学科学院医药生物技术研究所 | 2019-07-05 | — | — | CN | disclosed |
| CN-109743875-A | The inhibitor of MENIN-MLL interaction | 生命医药公司 | 2019-05-10 | — | — | CN | disclosed |
| CN-109476696-A | Anti-trypanosome and anti-leishmania agents for animals and humans | 细胞基因公司 | 2019-03-15 | — | — | CN | disclosed |
| CN-109311855-A | Compound and application thereof for inhibiting cyclophilin | 默克专利有限公司 | 2019-02-05 | — | — | CN | disclosed |
| CN-109153648-A | Benzazepine diformamide compound with teritary amide functional group | 豪夫迈·罗氏有限公司 | 2019-01-04 | — | — | CN | disclosed |
| CN-109071503-A | Compound and application thereof for inhibiting cyclophilin | 默克专利有限公司 | 2018-12-21 | — | — | CN | disclosed |
| CN-105392788-B | Substituted bridging urea analog as Sirtuin conditioning agent | 葛兰素史密斯克莱有限责任公司 | 2018-10-23 | — | — | CN | disclosed |
| CN-103951658-B | Sulfamide derivative for treating abnormal cell growth | 辉瑞产品公司 | 2017-10-13 | — | — | CN | disclosed |
| CN-107207496-A | Substituted bridged ring urea analogs as sirtuin modulators | 葛兰素史密斯克莱有限责任公司 | 2017-09-26 | — | — | CN | disclosed |
| US-20040077638-A1 | Novel integrin receptor antagonists | BASF AKTIENGESELLCHAFT (DE) | 2004-04-22 | — | — | US | disclosed |
| US-20040063934-A1 | Integrin ligands | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2004-04-01 | — | — | US | disclosed |
| CN-1374960-A | novel integrin receptor antagonists | BASF AG (DE) | 2002-10-16 | — | — | CN | disclosed |
| CN-1367785-A | Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing substituted phenylenediamine groups | AMERICAN HOME PROD (US) | 2002-09-04 | — | — | CN | disclosed |
| CN-1348446-A | Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing phenylenediamine groups | AMERICAN HOME PROD (US) | 2002-05-08 | — | — | CN | disclosed |
| CN-1335843-A | Thiourea inhibitors of herpes viruses | AMERICAN HOME PROD (US) | 2002-02-13 | — | — | CN | disclosed |
| CN-1333750-A | Acetamide and substituted acetamide-containing thiourea inhibitors of herpes viruses | AMERICAN HOME PROD (US) | 2002-01-30 | — | — | CN | disclosed |
| CN-1333769-A | Thiourea inhibitors of herps viruses | AMERICAN HOME PROD (US) | 2002-01-30 | — | — | CN | disclosed |
| CN-1332725-A | Thiourea inhibitors of herpes viruses | AMERICAN HOME PROD (US) | 2002-01-23 | — | — | CN | disclosed |
| CN-1329608-A | Alpha-methylbenzyl-containing thioure a inhibitors of herpes viruses containing phenylenediamine group | AMERICAN HOME PROD (US) | 2002-01-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063934-A1 | Integrin ligands | ITGB3, ITGAV, ITGAL | MEN1 4388/4885KMT2A 4601/4885SMN1; SMN2 3051/4885 |
| US-20040077638-A1 | Novel integrin receptor antagonists | ITGB3, ITGAV, ITGA2B | MEN1 4541/4885KMT2A 4233/4885SMN1; SMN2 3359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.